Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Editas Medicine, Inc. reported revenue of $41M, up 25.4% year over year. Operating margin was -394.9% and net margin -395.0%, on a free-cash-flow margin of -409.3% with capital expenditure at 1.5% of revenue. Every figure is computed directly from EDIT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $41M | -394.9% | -395.0% |
| FY2024 | $32M | -777.2% | -733.7% |
| FY2023 | $78M | -216.6% | -196.1% |
| FY2022 | $20M | -1146.3% | -1118.3% |
| FY2021 | $26M | -756.1% | -753.6% |
How does EDIT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.